Mostrar el registro sencillo del ítem
Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
dc.contributor.author | García-Escobar, I. | |
dc.contributor.author | Brozos Vázquez, Elena María | |
dc.contributor.author | Gutierrez Abad, D. | |
dc.contributor.author | Martínez-Marín, V. | |
dc.contributor.author | Pachón, V. | |
dc.contributor.author | Muñoz Martín, A. J. | |
dc.contributor.other | Cancer and Thrombosis Section of the Spanish Society of Medical Oncology (SEOM) | |
dc.date.accessioned | 2024-01-02T10:04:59Z | |
dc.date.available | 2024-01-02T10:04:59Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1699-048X | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/33206333 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/18529 | |
dc.description.abstract | Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K antagonists for the treatment of VTED and are associated with less frequent and severe bleeding. They have advantages over low-molecular-weight heparin, but comparative long-term efficacy and safety data are lacking for these compounds. Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efficacy and safety and the limited information in patients with cancer; in addition, we will briefly review their pharmacokinetic properties with special reference to potential interactions. | |
dc.language.iso | en | |
dc.rights | Atribución 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence | |
dc.type | Journal Article | es |
dc.authorsophos | García-Escobar, I.;Brozos-Vázquez, E.;Gutierrez Abad, D.;Martínez-Marín, V.;Pachón, V.;Muñoz Martín, A. J.;(SEOM), Cancer and Thrombosis Section of the Spanish Society of Medical Oncology | |
dc.identifier.doi | 10.1007/s12094-020-02506-4 | |
dc.identifier.pmid | 33206333 | |
dc.identifier.sophos | 43950 | |
dc.issue.number | 6 | |
dc.journal.title | Clinical & Translational Oncology | |
dc.organization | Servizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médica | |
dc.page.initial | 1034 | |
dc.page.final | 1046 | |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | Área Sanitaria de Santiago de Compostela e Barbanza | es |
dc.typefides | Artículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis) | es |
dc.typesophos | Artículo de Revisión | es |
dc.volume.number | 23 |